Deepa  Prasad net worth and biography

Deepa Prasad Biography and Net Worth

Director of Design Therapeutics

Deepa Prasad is the Executive Director of the Robinson Life Sciences Business and Entrepreneurship Program at University of California, Berkeley. Ms. Prasad recently served as president/CEO and a board member of vTv. Prior to vTv, Ms. Prasad was managing director at WestRiver Group, where she led investments in healthcare innovation across biotech and digital health/AI. Ms. Prasad has held various healthcare operational roles as chief of staff at Blue Shield of California, regional vice president for Optum, head of managed care at the California Hospital Association, and vice president, financial strategy and business development at Coherus Biosciences (CHRS). She began her career in investment banking working with biotech and pharma companies on private placements and buyside and sellside mergers and acquisitions, including cross-border M&A with several Japanese pharma. She currently serves on the grant funding committee for UC Davis and as a charter member for TiE, a non-profit global network of entrepreneurs and venture capitalists. Ms. Prasad earned her bachelor’s degree in business administration at the University of California, Berkeley and her M.B.A. from the Kellogg School of Management at Northwestern University with emphasis in finance and health industry management.

What is Deepa Prasad's net worth?

The estimated net worth of Deepa Prasad is at least $196.40 thousand as of December 18th, 2024. Ms. Prasad owns 20,000 shares of Design Therapeutics stock worth more than $196,400 as of December 5th. This net worth estimate does not reflect any other assets that Ms. Prasad may own. Learn More about Deepa Prasad's net worth.

How do I contact Deepa Prasad?

The corporate mailing address for Ms. Prasad and other Design Therapeutics executives is 6005 HIDDEN VALLEY ROAD SUITE 110, CARLSBAD CA, 92011. Design Therapeutics can also be reached via phone at 858-293-4900 and via email at [email protected]. Learn More on Deepa Prasad's contact information.

Has Deepa Prasad been buying or selling shares of Design Therapeutics?

Deepa Prasad has not been actively trading shares of Design Therapeutics in the last ninety days. Most recently, Deepa Prasad sold 3,806 shares of the business's stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $6.27, for a transaction totalling $23,863.62. Following the completion of the sale, the director now directly owns 20,000 shares of the company's stock, valued at $125,400. Learn More on Deepa Prasad's trading history.

Who are Design Therapeutics' active insiders?

Design Therapeutics' insider roster includes Rodney Lappe (Director), Deepa Prasad (Director), John Schmid (Director), and Arsani William (Director). Learn More on Design Therapeutics' active insiders.

Are insiders buying or selling shares of Design Therapeutics?

In the last year, insiders at the sold shares 1 times. They sold a total of 3,806 shares worth more than $23,863.62. The most recent insider tranaction occured on December, 18th when Director Deepa Prasad sold 3,806 shares worth more than $23,863.62. Insiders at Design Therapeutics own 23.5% of the company. Learn More about insider trades at Design Therapeutics.

Information on this page was last updated on 12/18/2024.

Deepa Prasad Insider Trading History at Design Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/18/2024Sell3,806$6.27$23,863.6220,000View SEC Filing Icon  
8/29/2023Buy12,000$2.31$27,720.0023,806View SEC Filing Icon  
See Full Table

Deepa Prasad Buying and Selling Activity at Design Therapeutics

This chart shows Deepa Prasad's buying and selling at Design Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Design Therapeutics Company Overview

Design Therapeutics logo
Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
Read More

Today's Range

Now: $9.82
Low: $9.33
High: $10.02

50 Day Range

MA: $7.21
Low: $5.53
High: $9.82

2 Week Range

Now: $9.82
Low: $2.60
High: $10.02

Volume

320,153 shs

Average Volume

514,527 shs

Market Capitalization

$559.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.63